Tuesday, October 27, 2020
Home Life Style Health & Fitness Two of Four Experimental Ebola Drugs Tests in Congo Saving Lives

Two of Four Experimental Ebola Drugs Tests in Congo Saving Lives

The preliminary findings prompted an early halt to a major study on the drugs and a decision to prioritize their use in the African country

Two of four experimental Ebola drugs being tested in Congo seem to be saving lives, international health authorities announced Monday.

The preliminary findings prompted an early halt to a major study on the drugs and a decision to prioritize their use in the African country, where a yearlong outbreak has killed more than 1,800 people.

The early results mark “some very good news,” said Dr. Anthony Fauci of the U.S. National Institutes of Health, which helped fund the study. With these drugs, “we may be able to improve the survival of people with Ebola.”

The two drugs — one developed by Regeneron Pharmaceuticals and the other by NIH researchers — are antibodies that work by blocking the virus.

Ebola, Drugs, Congo
FILE – A man receives a vaccine against Ebola from a nurse outside the Afia Himbi Health Center in Goma, July 15, 2019. VOA

While research shows there is an effective albeit experimental vaccine against Ebola — one now being used in Congo — no studies have signaled which of several potential treatments were best to try once people became sick. During the West Africa Ebola epidemic several years ago, studies showed a hint that another antibody mixture named ZMapp worked, but not clear proof.

So with the current outbreak in Congo, researchers compared ZMapp to three other drugs — Regeneron’s compound, the NIH’s called mAb114 and an antiviral drug named remdesivir.

On Friday, independent study monitors reviewed how the first several hundred patients in the Congo study were faring — and found enough difference to call an early halt to the trial. The panel determined that the Regeneron compound clearly was working better than the rest, and the NIH antibody wasn’t far behind, Fauci explained. Next, researchers will do further study to nail down how well those two compounds work.

The data is preliminary, Fauci stressed. But in the study, significantly fewer people died among those given the Regeneron drug or the NIH’s — about 30% compared to half who received ZMapp. More striking, when patients sought care early — before too much virus was in their bloodstream — mortality was just 6% with the Regeneron drug and 11% with the NIH compound, compared to about 24% for ZMapp, he said.

Also Read- Trump Administration Significantly Weakens U.S. Endangered Species Act

Among people who receive no care in the current outbreak, about three-fourths die, said Dr. Michael Ryan of the World Health Organization. All of Congo’s Ebola treatment units have access to the two drugs, he added, saying he was hopeful that the news would persuade more patients to seek care — as soon as symptoms appear.

Quick care ‘vital’

Tackling Congo’s outbreak has been complicated both by conflict in the region and because many people don’t believe Ebola is real and choose to stay at home when they’re sick, which spurs spread of the virus.

“Getting people into care more quickly is absolutely vital,” Ryan said. “The fact that we have very clear evidence now on the effectiveness of the drugs, we need to get that message out to communities.”

Ebola, Drugs, Congo
Two of four experimental Ebola drugs being tested in Congo seem to be saving lives, international health authorities announced Monday. Pixabay

Fauci said Regeneron and Ridgeback Biotherapeutics, which has licensed the NIH compound, told authorities enough doses are readily available.

Also Read- Amazon Launches its Marketplace Appstore in India

One issue researchers will have to analyze: Occasionally people who receive the Ebola vaccine still become sick, including some in the treatment study, which raises the question of whether their earlier protection inflated the drugs’ survival numbers. (VOA)

STAY CONNECTED

19,120FansLike
362FollowersFollow
1,779FollowersFollow

Most Popular

Women Experience Depression Even After 3 Years of Giving Birth

Researchers have found that approximately one in four women experienced high levels of depressive symptoms at some point in the three years after giving...

Lack of Monitoring Stations to Quantify Air Pollution in India

With Delhi facing another tryst with air pollution, several environmental experts believe that the problem goes beyond the national capital and that the country...

Nutritious Snacks for the Virtual School Breaks

The pandemic has forced children to go back to school with virtual learning having swapped classroom teaching. Although school in 2020 may look way...

Books that Address Children’s Mental Health

In these unprecedented times, when isolation fatigue, gloom, and the fear of losing a beloved has also come to grip children, taking care of...

Air Pollution Linked to 15% of COVID Deaths Worldwide

In a major global study, researchers have revealed that long-term exposure to air pollution may be linked to 15 percent of COVID-19 deaths worldwide. According...

Ketogenic Diet could Prevent or Reverse Heart Failure

Heart problems? A special diet might help as researchers have found that the popular and controversial ketogenic diet could completely prevent, or even reverse...

Technology to Produce Psychoactive Drugs by IIT Guwahati

Indian Institute of Technology Guwahati (IIT-G) on Tuesday said its researchers have developed a low-cost membrane technology to produce psychoactive drugs and anti-aging compounds...

Fashion Hubs Burgeon into Fresh Farm Outlets

In recent days, people passing by some of the biggest fashion hubs in Mumbai rub their eyes in disbelief at what they behold. Instead of...

Recent Comments